Welcome to our dedicated page for Minerva Neurosci news (Ticker: NERV), a resource for investors and traders seeking the latest updates and insights on Minerva Neurosci stock.
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company developing product candidates for central nervous system (CNS) disorders, with a lead focus on roluperidone for negative symptoms of schizophrenia. The NERV news feed on Stock Titan aggregates company-issued updates and market-moving disclosures so readers can follow how Minerva’s clinical, regulatory and financing milestones evolve over time.
Recent news from Minerva highlights its ongoing interactions with the U.S. Food and Drug Administration (FDA) following a Complete Response Letter to its New Drug Application for roluperidone, as well as the agency’s requirement for a confirmatory Phase 3 trial. The company has released details about the planned trial design, including patient selection criteria, dosing, and the primary efficacy endpoint based on the PANSS Marder negative symptoms factor score.
Investors tracking NERV can also find announcements about Minerva’s private placement financing involving Series A Convertible Preferred Stock and warrants, which the company expects to use to fund the confirmatory Phase 3 study, NDA resubmission, and preparation for a potential U.S. commercial launch of roluperidone, if approved. Additional news items cover quarterly and annual financial results, changes in research and development and general and administrative expenses, and updates on the company’s cash position.
Governance and leadership developments appear in the news flow as well, including the appointment of new directors with schizophrenia clinical trial experience and a consulting agreement intended to support roluperidone’s late-stage development. For readers interested in CNS drug development, regulatory strategy, and biotech financing structures, the NERV news page provides a centralized view of Minerva’s public communications. Bookmark this page to review new press releases, earnings updates and material 8-K disclosures as they are reported.
Minerva Neurosciences (Nasdaq: NERV) announced a leadership transition: Jim O’Connor will join as Chief Business Officer and General Counsel, effective April 21, 2026, while President Geoff Race has elected to leave and will remain engaged as a consultant. The company said the board has confidence in O’Connor to advance roluperidone into the next planned Phase 3 trial.
Minerva Neurosciences (Nasdaq: NERV) screened the first patient in its global confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia on March 31, 2026. The trial will enroll ~380 patients across ~40 sites including the US and Europe.
The study follows prior pivotal Phase 2b and Phase 3 trials that showed consistent improvements at the 64 mg dose. Efficacy topline data are expected in 2H 2027, and the design reflects prior FDA discussions.
Minerva Neurosciences (Nasdaq: NERV) presented results from an open‑label safety trial of roluperidone co‑administered with olanzapine at SIRS 2026.
The trial reported no clinically significant adverse effects, no meaningful pharmacokinetic changes, and no pharmacodynamic changes during combined administration. A confirmatory Phase 3 is enrolling with topline data anticipated in H2 2027.
Minerva Neurosciences (Nasdaq: NERV) will present at The Stifel 2026 Virtual CNS Forum on March 18, 2026 at 8:30 AM ET.
Remy Luthringer, PhD, Executive Chairman & CEO, will deliver the company presentation; a replay will be available on the company’s Investors & Media Events and Presentations webpage for ninety days.
Minerva Neurosciences (Nasdaq: NERV) reported Q4 and FY2025 results and business updates on March 11, 2026. The company completed an $80.0M upfront private placement with potential additional proceeds up to $120.0M contingent on warrant exercises and trial outcomes.
Minerva plans to initiate a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia in Q2 2026 (~380 patients, 12-week primary endpoint) with topline data expected in 2H 2027. Cash was ~$82.4M at December 31, 2025; GAAP net loss for 2025 was $293.4M driven by non-cash preferred stock and warrant accounting.
Minerva Neurosciences (Nasdaq: NERV) announced that Remy Luthringer, PhD, Executive Chairman & Chief Executive Officer, will present at The Citizens Life Sciences Conference in Miami on March 10-11, 2026.
The company will deliver a company presentation on Tuesday, March 10 at 9:35 AM ET; a live webcast and a replay available for ninety days will be provided, according to the company.
Minerva Neurosciences (NASDAQ: NERV) will host a virtual key opinion leader event on Feb 3, 2026 at 10:30 AM ET to discuss roluperidone and the unmet need of negative symptoms of schizophrenia. Speakers Gregory Strauss, PhD, and Brian Kirkpatrick, MD, MSPH, will join management to review patient burden, assessment challenges in the current regulatory environment, and how Minerva's planned confirmatory Phase 3 trial in 2026 uses a novel protocol aligned with FDA considerations to maximize the probability of success. A live Q&A will follow the presentations.
Minerva Neurosciences (Nasdaq: NERV) appointed Dr. Inderjit Kaul to its board of directors and engaged him as a consultant for the clinical development of roluperidone.
The company said it recently raised up to $200 million in a private placement to fund a confirmatory Phase 3 trial of roluperidone, resubmission of its NDA, and preparation for a potential US commercial launch. Minerva plans to add board members with schizophrenia trial experience to support the Phase 3 program.
Minerva Neurosciences (Nasdaq: NERV) reported Q3 2025 results and business updates on November 5, 2025. The company completed a private placement that generated $80 million in upfront gross proceeds on October 23, 2025, with up to an additional $200 million available if Tranche A and B warrants are exercised under specified conditions, including a Phase 3 primary endpoint. Management said the financing and FDA alignment enable a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia. Cash and equivalents were approximately $12.4 million at September 30, 2025. Q3 net loss was $2.7 million and nine-month net loss was $9.8 million.
Minerva Neurosciences (Nasdaq: NERV) announced a private placement providing up to $200 million in gross proceeds to advance roluperidone for negative symptoms of schizophrenia.
The financing includes an $80 million upfront Series A preferred stock sale, up to $80 million from Tranche A warrant exercises, and $40 million contingent on a milestone tied to Tranche B warrant cash exercises. Minerva says proceeds are expected to fund the confirmatory Phase 3 trial, NDA resubmission and U.S. commercial readiness; closing is expected on or about October 23, 2025. Up to three investor‑designated directors will be added to the board to support clinical operations.